Oncology Brothers shared a post on X:
“Vepdegestrant (PROTAC ER degrader) FDA for HR+ metastatic breast based off Veritac2 Ph III vs. (Fulvestrant) after CDK4/6i + AI:
- mPFS 5.0 vs 2.1 mos in ESR1m (HR=0.57)
- OS is immature
- Well-tolerated, low discontinuation.”
Sarah Premji, Physician at SCRI Oncology Partners, shared this post, adding:
“Presented at ASCO 2025 by Erika Hamilton! So proud to work with and learn from her every day at SCRI Oncology Partners!
PROTAC first of its kind for an approval, utilizing the ubiquitin-proteasome system in order to directly and potently degrade the estrogen receptor, statistically significant improvements in mPFS in ESR1 mutated population!
A win for HR+ BC! Multiple endocrine agents in combo with targeted agents being studied in trials now.”